Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | The relevance of MRD for CLL in the era of targeted therapies

Lydia Scarfò • 2 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax
CLARITY

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, talks on the relevance of measurable residual disease (MRD) for chronic lymphocytic leukemia (CLL) in the era of targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lydia Scarfò

1:56
Defining success in CLL
Lydia Scarfò • 8 Oct 2023
2:00
Prevention of TLS with venetoclax-based regimens
Lydia Scarfò • 8 Oct 2023
1:28
Challenges with defining fitness in CLL & important comorbidities to consider when selecting therapy
Lydia Scarfò • 8 Oct 2023
2:08
Choosing between continuous versus fixed-duration therapy in CLL
Lydia Scarfò • 8 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals